{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:29:22Z","timestamp":1791584962744,"version":"4.3.4"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473781"],"award-info":[{"award-number":["82473781"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173652"],"award-info":[{"award-number":["82173652"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["BK20221522"],"award-info":[{"award-number":["BK20221522"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20221522"],"award-info":[{"award-number":["BK20221522"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017534","name":"333 Project of Jiangsu Province","doi-asserted-by":"publisher","award":["2022-3-16-203"],"award-info":[{"award-number":["2022-3-16-203"]}],"id":[{"id":"10.13039\/501100017534","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.119049","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:27:33Z","timestamp":1781159253000},"page":"119049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Rewiring cell death and evading repair: Evolution of temozolomide and emerging strategies against resistant glioblastoma"],"prefix":"10.1016","volume":"316","author":[{"given":"Lan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengfei","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengkun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5109-0304","authenticated-orcid":false,"given":"Haopeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejmech.2026.119049_bib1","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.3390\/cancers14102412","article-title":"Epidemiology of glioblastoma multiforme\u2013literature review","volume":"14","author":"Grochans","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119049_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/noajnl\/vdab051","article-title":"Multiparametric MRI texture analysis in prediction of glioma biomarker status: added value of MR diffusion","volume":"3","author":"Kihira","year":"2021","journal-title":"Neuro-Oncology Adv"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119049_bib3","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119049_bib4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119049_bib5","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: a review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119049_bib6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11060-020-03448-1","article-title":"A review of glioblastoma immunotherapy","volume":"151","author":"Medikonda","year":"2021","journal-title":"J. Neuro Oncol."},{"issue":"17","key":"10.1016\/j.ejmech.2026.119049_bib7","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.3390\/cancers14174244","article-title":"An orthotopic model of glioblastoma is resistant to radiodynamic therapy with 5-AminoLevulinic acid","volume":"14","author":"Dupin","year":"2022","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.ejmech.2026.119049_bib8","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of Nivolumab vs Bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119049_bib9","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-Expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"issue":"23","key":"10.1016\/j.ejmech.2026.119049_bib10","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119049_bib11","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a society for neuro-Oncology (SNO) and European society of neuro-oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119049_bib12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12951-025-03406-x","article-title":"Oxidative stress induced paclitaxel-derived carbon dots inhibit glioblastoma proliferation and EMT process","volume":"23","author":"Haiyang","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119049_bib13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s12951-022-01584-6","article-title":"Tumor-derived small extracellular vesicles: potential roles and mechanism in glioma","volume":"20","author":"Guo","year":"2022","journal-title":"J. Nanobiotechnol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119049_bib14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/jhet.5570180406","article-title":"Reactions with Diazoazoles. Part IV. . [7 + 2]\u2010 and [11 + 2]\u2010cyclocondensation Reactions of Diazoazoles with Acyltriphenylphosphonium Methylides to Azolo [5,1\u2010 c] [1,2,4] Triazines","volume":"18","author":"Ege","year":"1981","journal-title":"J. Heterocycl. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119049_bib15","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1021\/jm00368a016","article-title":"Antitumour imidazotetrazines. 1. Synthesis and chemistry of 8-Carbamoyl-3-(2-Chloroethyl) Imidazo[5,1-d]-1,2,3,5-Tetrazin-4(3H)-One, a novel broad-spectrum antitumor agent","volume":"27","author":"Stevens","year":"1984","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2026.119049_bib16","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/0006-2952(76)90521-9","article-title":"Alteration of DNA by 5-(3-Methyl-1- triazeno) Imidazole-4-Carboxamide (NSC-407347)","volume":"25","author":"Mizuno","year":"1976","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119049_bib17","first-page":"342","article-title":"Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-Methyl-(Triazen-1-Yl) Imidazole-4-Carboxamide, cancer chemother","volume":"27","author":"Tsang","year":"1991","journal-title":"Pharmacol."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119049_bib18","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0959-8049(05)80221-7","article-title":"From triazines and triazenes to temozolomide","volume":"29","author":"Stevens","year":"1993","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.ejmech.2026.119049_bib19","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0959-8049(05)80198-4","article-title":"Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours","volume":"29","author":"O'Reilly","year":"1993","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119049_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0305-7372(97)90019-0","article-title":"Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials","volume":"23","author":"Newlands","year":"1997","journal-title":"Cancer Treat Rev."},{"issue":"22","key":"10.1016\/j.ejmech.2026.119049_bib21","first-page":"5846","article-title":"Antitumor activity and pharmacokinetics in mice of 8-Carbamoyl-3-Methyl-Imidazo[5,1-d]-1,2,3,5-Tetrazin-4(3H)-One (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine","volume":"47","author":"Stevens","year":"1987","journal-title":"Cancer Res."},{"issue":"31","key":"10.1016\/j.ejmech.2026.119049_bib22","doi-asserted-by":"crossref","first-page":"9045","DOI":"10.1021\/bi00197a003","article-title":"NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA","volume":"33","author":"Denny","year":"1994","journal-title":"Biochemistry"},{"issue":"23","key":"10.1016\/j.ejmech.2026.119049_bib23","first-page":"6449","article-title":"Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review","volume":"49","author":"Vaupel","year":"1989","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119049_bib24","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1039\/D3CB00076A","article-title":"Antitumour imidazotetrazines: past, present\u2026 and future?","volume":"4","author":"Stevens","year":"2023","journal-title":"RSC Chem. Biol."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119049_bib25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2176\/nmc.ra.2018-0141","article-title":"Potential strategies overcoming the temozolomide resistance for glioblastoma","volume":"58","author":"Jiapaer","year":"2018","journal-title":"Neurol. Med.-Chir."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119049_bib26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41419-025-07363-z","article-title":"Overexpression of miR-124 enhances the therapeutic benefit of TMZ treatment in the orthotopic GBM mice model by inhibition of DNA damage repair","volume":"16","author":"Yucheng","year":"2025","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119049_bib27","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1038\/s41467-020-17717-0","article-title":"MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas","volume":"11","author":"Oldrini","year":"2020","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119049_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/JCI203730","article-title":"Mismatch repair deficiency reshapes glioblastoma through immune suppression rather than hypermutation","volume":"136","author":"Li","year":"2026","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119049_bib29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat. Cell Biol."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119049_bib30","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41419-018-0981-3","article-title":"PARP-1-Dependent RND1 transcription induced by topoisomerase I cleavage complexes confers cellular resistance to Camptothecin","volume":"9","author":"Mouly","year":"2018","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119049_bib31","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/nu8070396","article-title":"Mangiferin and cancer: mechanisms of action","volume":"8","author":"Gold-Smith","year":"2016","journal-title":"Nutrients"},{"key":"10.1016\/j.ejmech.2026.119049_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2013.00008","article-title":"Response to DNA damage: why do we need to focus on protein phosphatases?","volume":"3","author":"Shimada","year":"2013","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119049_bib33","first-page":"869","article-title":"New insight into targeting the DNA damage response in the treatment of glioblastoma","volume":"22","author":"Tengfei","year":"2024","journal-title":"Chin. J. Nat. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119049_bib34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.20892\/j.issn.2095-3941.2023.0011","article-title":"Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance","volume":"20","author":"Junhu","year":"2023","journal-title":"Cancer Biol. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119049_bib35","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1021\/acs.jmedchem.3c00223","article-title":"Somatostatin receptor Subtype-2 targeting system for specific delivery of temozolomide","volume":"67","author":"AghaAmiri","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119049_bib36","article-title":"Nanotherapeutics overcoming the blood-brain barrier for glioblastoma treatment","volume":"12","author":"Lin","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119049_bib37","article-title":"Recent progress in DNA methyltransferase inhibitors as anticancer agents","volume":"13","author":"Zhixiong","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119049_bib38","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1158\/1078-0432.CCR-05-2198","article-title":"Lomeguatrib, a potent inhibitor of O 6-Alkylguanine-DNA-Alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors","volume":"12","author":"Ranson","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119049_bib39","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1215\/15228517-2009-007","article-title":"Phase I trial of temozolomide plus O6-Benzylguanine 5-Day regimen with recurrent malignant glioma","volume":"11","author":"Quinn","year":"2009","journal-title":"Neuro Oncol."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119049_bib40","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.2008.18.8417","article-title":"Phase II trial of temozolomide plus O6 -Benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma","volume":"27","author":"Quinn","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119049_bib41","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41420-023-01775-6","article-title":"Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets","volume":"9","author":"Hailong","year":"2023","journal-title":"Cell Death Discov."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119049_bib42","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41419-022-05497-y","article-title":"BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression","volume":"13","author":"Tancredi","year":"2022","journal-title":"Cell Death Dis."},{"issue":"22","key":"10.1016\/j.ejmech.2026.119049_bib43","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.3390\/cancers17223604","article-title":"RBM39 contributes to MGMT maintenance in response to temozolomide-induced DNA damage","volume":"17","author":"Khalaj","year":"2025","journal-title":"Cancers"},{"issue":"17","key":"10.1016\/j.ejmech.2026.119049_bib44","doi-asserted-by":"crossref","first-page":"7120","DOI":"10.1021\/jm401121k","article-title":"Synthesis and quantitative structure\u2013activity relationship of imidazotetrazine prodrugs with activity independent of O 6-Methylguanine-DNA-Methyltransferase, DNA mismatch repair, and P53","volume":"56","author":"Pletsas","year":"2013","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119049_bib45","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1021\/acschembio.2c00022","article-title":"Novel imidazotetrazine evades known resistance mechanisms and is effective against temozolomide-resistant brain cancer in cell culture","volume":"17","author":"Svec","year":"2022","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119049_bib46","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3389\/fonc.2019.00485","article-title":"C8-Substituted imidazotetrazine analogs overcome temozolomide resistance by inducing DNA adducts and DNA damage","volume":"9","author":"Yang","year":"2019","journal-title":"Front. Oncol."},{"issue":"30","key":"10.1016\/j.ejmech.2026.119049_bib47","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1039\/D0RA02686G","article-title":"A novel series of phenolic temozolomide (TMZ) esters with 4 to 5-Fold increased potency, compared to TMZ, against glioma cells irrespective of MGMT expression","volume":"10","author":"Shervington","year":"2020","journal-title":"RSC Adv."},{"issue":"18","key":"10.1016\/j.ejmech.2026.119049_bib48","doi-asserted-by":"crossref","first-page":"18810","DOI":"10.1021\/acs.jmedchem.5c02019","article-title":"Temozolomide-derived therapeutic strategies to overcome resistance in glioblastoma","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"6228","key":"10.1016\/j.ejmech.2026.119049_bib49","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.aaa1299","article-title":"Targeting LDH enzymes with a stiripentol analog to treat epilepsy","volume":"347","author":"Sada","year":"2015","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.ejmech.2026.119049_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202309290","article-title":"Histone H3K9 lactylation confers temozolomide resistance in glioblastoma via LUC7L2\u2010Mediated MLH1 intron retention","volume":"11","author":"Yue","year":"2024","journal-title":"Adv. Sci."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119049_bib51","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.dnarep.2007.03.008","article-title":"MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents","volume":"6","author":"Kaina","year":"2007","journal-title":"DNA Repair"},{"issue":"14","key":"10.1016\/j.ejmech.2026.119049_bib52","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1158\/1078-0432.CCR-08-3012","article-title":"MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance","volume":"15","author":"Yip","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.ejmech.2026.119049_bib53","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1158\/0008-5472.CAN-14-3616","article-title":"Minor changes in expression of the mismatch repair protein MSH2 exert a major impact on glioblastoma response to temozolomide","volume":"75","author":"McFaline-Figueroa","year":"2015","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119049_bib54","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrc3088","article-title":"DNA interstrand crosslink repair and cancer","volume":"11","author":"Deans","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119049_bib55","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.dnarep.2019.04.007","article-title":"DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas","volume":"78","author":"Kaina","year":"2019","journal-title":"DNA Repair"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119049_bib56","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/neuonc\/noae257","article-title":"The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma","volume":"27","author":"McCord","year":"2025","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119049_bib57","first-page":"17","article-title":"Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review","volume":"4","author":"Singh","year":"2021","journal-title":"Cancer Drug Resist"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119049_bib58","doi-asserted-by":"crossref","first-page":"14125","DOI":"10.1080\/21655979.2022.2081463","article-title":"SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-Mediated autophagy","volume":"13","author":"Jie","year":"2022","journal-title":"Bioengineered"},{"issue":"4","key":"10.1016\/j.ejmech.2026.119049_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035104","article-title":"Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death","volume":"7","author":"Cheng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119049_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107998","article-title":"Synthesis and characterization of a novel naphthalimide-selenium based temozolomide drug conjugate in glioma cells","volume":"154","author":"Sharma","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119049_bib61","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.ejmech.2026.119049_bib62","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41568-019-0149-1","article-title":"Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion","volume":"19","author":"Friedmann Angeli","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119049_bib63","article-title":"A targetable PRR11-DHODH axis drives Ferroptosis- and temozolomide-resistance in glioblastoma","volume":"73","author":"Zong","year":"2024","journal-title":"Redox Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119049_bib64","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41420-025-02857-3","article-title":"Novel imidazotetrazine derivatives overcome temozolomide resistance in glioblastoma by inducing ferroptosis and apoptosis","volume":"12","author":"Heng","year":"2026","journal-title":"Cell Death Discov."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119049_bib65","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1158\/1535-7163.MCT-13-0964","article-title":"NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas","volume":"13","author":"Cho","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"issue":"17","key":"10.1016\/j.ejmech.2026.119049_bib66","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3390\/cells13171442","article-title":"PDCD10 is a key player in TMZ-resistance and tumor cell regrowth: insights into its underlying mechanism in glioblastoma cells","volume":"13","author":"Zhu","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2026.119049_bib67","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3389\/fonc.2020.01377","article-title":"PDCD10-Deficiency promotes malignant behaviors and tumor growth via triggering EphB4 kinase activity in glioblastoma","volume":"10","author":"Wan","year":"2020","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119049_bib68","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1111\/cas.70198","article-title":"Design and evaluation of Eb4Mab-7-mG2a: a dual-action Anti-EphB4 monoclonal antibody for targeted breast cancer therapy","volume":"116","author":"Ohishi","year":"2025","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119049_bib69","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrc3185","article-title":"Balancing repair and tolerance of DNA damage caused by alkylating agents","volume":"12","author":"Fu","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.ejmech.2026.119049_bib70","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3390\/cells11071215","article-title":"Transcriptomic profiling of DNA damage response in patient-derived glioblastoma cells before and after radiation and temozolomide treatment","volume":"11","author":"Lozinski","year":"2022","journal-title":"Cells"},{"issue":"21","key":"10.1016\/j.ejmech.2026.119049_bib71","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"issue":"6330","key":"10.1016\/j.ejmech.2026.119049_bib72","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"7035","key":"10.1016\/j.ejmech.2026.119049_bib73","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nature03482","article-title":"DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis","volume":"434","author":"Bartkova","year":"2005","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119049_bib74","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41571-024-00966-z","article-title":"Synthetic lethal strategies for the development of cancer therapeutics","volume":"22","author":"Ngoi","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119049_bib75","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of Poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"7035","key":"10.1016\/j.ejmech.2026.119049_bib76","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-Deficient tumours with inhibitors of Poly(ADP-Ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"375","key":"10.1016\/j.ejmech.2026.119049_bib77","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119049_bib78","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3390\/biom11081188","article-title":"BRCAness as a biomarker of susceptibility to PARP inhibitors in glioblastoma multiforme","volume":"11","author":"Xavier","year":"2021","journal-title":"Biomolecules"},{"issue":"13","key":"10.1016\/j.ejmech.2026.119049_bib79","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1158\/0008-5472.CAN-09-4295","article-title":"PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or Poly(ADP-Ribose) polymerase inhibitors","volume":"70","author":"McEllin","year":"2010","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119049_bib80","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1963","article-title":"Poly(ADP-Ribose): novel functions for an old molecule","volume":"7","author":"Schreiber","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119049_bib81","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2012-12-472845","article-title":"Parp-2 is required to maintain hematopoiesis following sublethal \u03b3-Irradiation in mice","volume":"122","author":"Farr\u00e9s","year":"2013","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.ejmech.2026.119049_bib82","doi-asserted-by":"crossref","first-page":"14498","DOI":"10.1021\/acs.jmedchem.1c01012","article-title":"Discovery of 5-{4-[(7-Ethyl-6-Oxo-5,6-Dihydro-1,5-Naphthyridin-3-Yl)Methyl]Piperazin-1-Yl}- N -Methylpyridine-2-Carboxamide (AZD5305): A PARP1\u2013DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs","volume":"64","author":"Johannes","year":"2021","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2026.119049_bib83","doi-asserted-by":"crossref","first-page":"21717","DOI":"10.1021\/acs.jmedchem.4c01725","article-title":"Discovery of 6-Fluoro-5-{4-[(5-Fluoro-2-Methyl-3-Oxo-3,4-Dihydroquinoxalin-6-Yl)Methyl]Piperazin-1-Yl}- N -Methylpyridine-2-Carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor","volume":"67","author":"Johannes","year":"2024","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119049_bib84","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1158\/1078-0432.CCR-23-2094","article-title":"Preclinical characterization of AZD9574, a blood\u2013brain barrier penetrant inhibitor of PARP1","volume":"30","author":"Staniszewska","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119049_bib85","first-page":"3359","article-title":"PCNA unloading is crucial for the bypass of DNA lesions using homologous recombination","volume":"25","author":"Arbel-Groissman","year":"2024","journal-title":"Int. J. Math. Stat."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119049_bib86","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/s41467-024-45979-5","article-title":"Trans-lesion synthesis and mismatch repair pathway crosstalk defines chemoresistance and hypermutation mechanisms in glioblastoma","volume":"15","author":"Xing","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119049_bib87","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cell.2019.05.028","article-title":"A small molecule targeting mutagenic translesion synthesis improves chemotherapy","volume":"178","author":"Wojtaszek","year":"2019","journal-title":"Cell"},{"issue":"46","key":"10.1016\/j.ejmech.2026.119049_bib88","doi-asserted-by":"crossref","first-page":"28918","DOI":"10.1073\/pnas.2016064117","article-title":"REV1 inhibitor JH-RE-06 enhances tumor cell response to chemotherapy by triggering senescence hallmarks","volume":"117","author":"Chatterjee","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119049_bib89","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ijc.21866","article-title":"L \u2010type amino acid transporter 1 as a potential molecular target in human astrocytic tumors","volume":"119","author":"Nawashiro","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119049_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106661","article-title":"Specific transport of temozolomide does not override DNA repair-mediated chemoresistance","volume":"195","author":"Bahrami","year":"2024","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119049_bib91","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1007\/s12274-023-5568-3","article-title":"LAT1 targeted brain delivery of temozolomide and sorafenib for effective glioma therapy","volume":"16","author":"Yufei","year":"2023","journal-title":"Nano Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:38:05Z","timestamp":1785904685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426004940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":91,"alternative-id":["S0223523426004940"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119049","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rewiring cell death and evading repair: Evolution of temozolomide and emerging strategies against resistant glioblastoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119049"}}